EGFR-targeted therapies in the post-genomic era.

about

Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.Modular Nanotransporters for Nuclear-Targeted Delivery of Auger Electron Emitters

P2860

Q55518643-F0C78A02-9FDB-4B2A-861A-ADF672882D2F Q58700796-265C3724-C9A0-4B5F-A569-4214DB793674

P2860

EGFR-targeted therapies in the post-genomic era.

Item

http://www.wikidata.org/entity/Q45871491

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

EGFR-targeted therapies in the post-genomic era.

@en

EGFR-targeted therapies in the post-genomic era.

@nl

type

Item

label

EGFR-targeted therapies in the post-genomic era.

@en

EGFR-targeted therapies in the post-genomic era.

@nl

prefLabel

EGFR-targeted therapies in the post-genomic era.

@en

EGFR-targeted therapies in the post-genomic era.

@nl

P1476

EGFR-targeted therapies in the post-genomic era.

@en

P2093

Daniel E Johnson

http://www.w3.org/2001/XMLSchema#string

Mary Jue Xu

http://www.w3.org/2001/XMLSchema#string

P2860

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules

Therapeutic insights from genomic studies of head and neck squamous cell carcinomas

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

P2888

s10555-017-9687-8

P304

463-473

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10555-017-9687-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer Grandis

P577

2017-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091422681

http://www.w3.org/2001/XMLSchema#string

P698

28866730

http://www.w3.org/2001/XMLSchema#string

P932

5693744

http://www.w3.org/2001/XMLSchema#string

EGFR-targeted therapies in the post-genomic era.

about

P2860

P2860

EGFR-targeted therapies in the post-genomic era.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932